CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College.

Slides:



Advertisements
Similar presentations
 Most common and important degenerative disease of the brain  Shrinkage in size and weight of the brain  Severe degree of diffuse cerebral atrophy.
Advertisements

APOE Genotype Effects on Alzheimer’s Disease Clinical Onset, Epidemiology, and Gompertzian Aging Functions J.Wesson Ashford, M.D., Ph.D. Stanford / VA.
Dementia with Lewy bodies The more who know, the fewer who suffer.
Frontotemporal Dementia
Screening for Alzheimer’s disease Herman Buschke, MD Einstein Aging Study (NIA AG-03949) Department of Neurology Albert Einstein College of Medicine.
Alzheimer’s Disease By Juan Escobar Per: 4. Alzheimer’s Disease  A common form of dementia of unknown cause, usually beginning in late middle age, characterized.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
CN-1 Neuropathology of Parkinson’s Disease Dementia James B. Leverenz, MD Associate Professor Neurology and Psychiatry and Behavioral Sciences University.
Parkinson’s Disease Dementia (PDD) A Clinical Perspective
Dementia with Lewy Bodies
Alexander I. Tröster, Ph.D. Department of Neurology
LEWY BODY DEMENTIA Hena Jawaid PGY-III. Also known as …. LBD - hena jawaid 2  Cortical lewy body disease  Lewy body variant of Alzheimer’s disease 
Mild Cognitive Impairment
How Alzheimer’s Disease Differs from Frontal Temporal Lobe Dementia (Pick’s Disease) Josepha A. Cheong, MD University of Florida Departments of Psychiatry.
Dr. Omranifard MD 12 may 2015 Depression is one of the most prevalent psychiatric disorders in late life with devastating health consequences. It could.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Dementia Research Group MRI, rates of atrophy and Alzheimer’s disease Nick Fox Dementia Research Group Institute of Neurology, UCL Queen Square, London.
Alzheimer’s Assessment Assessing the Cognitive-Linguistic effects of Alzheimer’s.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part A – AD definition, neuropath? NUCLEAR MEDICINE GRAND.
Non-medication Management of Agitated Behavior in Dementia Patients Josepha A. Cheong, MD University of Florida Departments of Psychiatry and Neurology.
Treatment of Parkinson’s Disease Dementia (PDD) Shanil Ebrahim.
CI-1 Exelon ® (rivastigmine) United States Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee May 17, 2006.
Alzheimer’s Disease Landscape
Cognitive Impairment in Parkinson’s Disease
Non-Alzheimer’s Dementias
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
THE COGNITIVE DISORDERS Brian E. Wood, D.O. Associate Professor and Chair Department of Neuropsychiatry and Behavioral Sciences Edward Via Virginia College.
Procedures Manual, Control Series, & Phenotype Committee Update Stephanie Doan, MPH NIA AD Genetics Initiative Co-Coordinator Columbia University.
Parkinson’s Plus By: Glen Estrosos.
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Dementia: Delivering the Diagnosis Daniel D. Christensen, M.D. Clinical Professor of Psychiatry Clinical Professor of Neurology Adjunct Professor of Pharmacology.
Jack Twersky, MD Medical Director CLC Durham.  Memory impairment and at least one of the following  Aphasia  Apraxia  Agnosia  Executive function.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.
HOW TO EXAMINE PATIENTS WITH DEMENTIA Serge Gauthier, MD, FRCPC McGill Centre for Studies in Aging Douglas Mental Health Research Institute.
The Dementias Dr Giles Richards Consultant Psychiatrist CFT.
CD-1 Rationale for Indication of Parkinson’s Disease Dementia (PDD) and Study Design Roger Lane, MD, MPH Disease Area Section Head for Dementia Neuroscience.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting - March 14, Issues Related to the Development of Drugs for the Treatment.
Assessment and Diagnosis of Dementia Dr Alison Haddow.
CAROLINE HARADA, M.D. ASSOCIATE PROFESSOR OF MEDICINE UAB DIVISION OF GERONTOLOGY, GERIATRICS, AND PALLIATIVE CARE NOVEMBER 2013 Dementia.
The Alzheimer’s Disease Challenge: Take Your Knowledge Further ALZHEIMER’S DISEASE AND ITS MANAGEMENT: AN OVERVIEW.
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Pathogenesis and pathology of parkinsonism
Alzheimer's By Emily Toro Period 1.
Emma Hahs, Brooke Armistead, Sarah Brown, Sok Kean Khoo Department of Cell and Molecular Biology, College of Liberal Arts and Sciences, Grand Valley State.
Types of Dementia Dr Bernie Coope Associate Medical Director/Honorary Senior Lecturer, Worcester University Association for Dementia Studies.
Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA
DEMENTIA 1/6/16 DR TONY O’BRIEN MD FRCP. Dementia Common – 700,000 sufferers in the UK Common – 700,000 sufferers in the UK Prevalence increases with.
Parkinson’s Disease.
The Malfunctioning Mind: Degenerative Diseases of the Brain
59 year old man w visual hallucinations
Dementia with Lewy Bodies
M. M. Dumitru¹∙², V.Chirita¹∙², R.Chirita¹∙²
The Malfunctioning Mind: Degenerative Diseases of the Brain
#14-A-1124 AAN Department of Neurology and Epidemiology, University of Oklahoma Medical Center; Oklahoma City, OK Cognitive and Behavioral Changes in PSP:
Polypharmacy and specific medication profiles as predictors of treatment and health outcomes in dementia Dr Christoph Mueller, NIHR Academic Clinical Lecturer.
Poststroke dementia Vikas Dhikav,
PPMI in the Medical Literature
Figure 2 Overview of risk factors for Parkinson disease dementia
Figure 1 Diagnostic tiers of Parkinson disease as single disease
Mark S. Forman, Virginia M-Y. Lee, John Q. Trojanowski  Neuron 
Assessment of BPSD Rajesh Tampi , MD Professor of Psychiatry
Neurobiology of BPSD Rajesh Tampi , MD Professor of Psychiatry
Postmortem Neurological Diagnosis A Postmortem Neurological Diagnosis or Brain-Only Autopsy, is the only definitive answer for families or researchers.
Presentation transcript:

CU-1 Summary of Neuropathological and Clinical Features of PDD Clive Ballard, MD Professor of Age Related Diseases Institute of Psychiatry King’s College London

CU-2 Overview  PDD is a distinct dementia syndrome  PDD can be diagnosed unambiguously in routine clinical practice  PDD is a rational target for treatment

CU-3 Study by Clinical informationNeuropathology NFamiliesLewy bodiesGenetic findings Golbe et al, 1990, 1996; Duda et al, SN + NCA53T SNCA mutation Waters and Miller, 1994; Muenter et al, 1998; Farrer et al, 1999; Singleton et al, SN + NCPARK4. SNCA gene triplication. Spira et al, SN + NCA53T SNCA mutation Ohtake et al, Autopsy not performed V70M beta synuclein mutation Krüger et al, 1998, Autopsy not performed A30P SNCA mutation Zarranz et al, SN + NCE46K SNCA mutation Genetic Associations of PDD in Familial PD— Kurz et al, 2006 † SN = Sub-stantia nigra; NC = Neocortex. † Kurz et al. Dementia and Geriatr Cog Disorders. In press.

CU-4 Relationship Between Pathology and Duration of PD Before Dementia Plaques (CERAD) n (%) Braak stage n (%) Meet diagnostic criteria for AD n (%) DLB (n = 29) †§ Frequent 19 (66) 5/6 3 (10)9 (31) PD for yr before dementia (n = 14) †‡ Frequent 2 (14) 5/6 2 (14) 2 (7) PD for > 9.5 yr before dementia (n = 14) †‡ Frequent 3 (21)5/6 0 (0) † Aarsland D, et al. Ann Neurol. 2005:58; ‡ Perry R, et al. Neurol In press. § Ballard C, et al. Am J Psychiat. 2004:161;

CU-5 PDD Predicts a Characteristic Neuropathologic and Clinical Profile  Lewy body pathology (LBP) is the predominant substrate of cognitive decline in PDD  Overlapping AD plaque pathology is not the main correlate of dementia in PDD patients  93% to 94% of patients with PDD lack sufficient pathologic changes to meet diagnostic criteria for AD  Dementia in PDD has a characteristic profile of neuropsychiatric, cognitive, neurologic, and autonomic features

CU-6 Attention and Fluctuating Attention in PDD and AD Ballard C, et al. Neurology. 2002; 59: p <

CU-7 Clinical Symptoms of PDD vs AD PDD (N = 34) AD (N = 92) Major depression 28% 8% Fluctuation 82% 4% Falls 71%21% Visual hallucinations 74%16% Parkinsonism100% 7% Ballard C, et al. Am J Psych. 1999;156: Ballard C, et al. J Clin Psych. 2001;2001:46-49.

CU-8 Median (IQR) Diagnosis Control (N = 42) AD (N = 39) PDD (N = 40) Median of mean change in heart rate during deep breathing 7.4 ( ) 7.5 ( ) 3.3 ( ) Median Valsalva Ratio1.33 ( ) 1.34 ( ) 1.14 ( ) Median heart rate response to standing 1.14 ( ) 1.10 ( ) 1.04 ( ) Autonomic Function (Parasympathetic) in AD and PDD PDD vs. AD: p-value <0.05 for all comparisons. PDD vs. Controls: p-value <0.001 for all comparisons. Kenny RA, et al. Dementia with Lewy Bodies and Parkinson’s Disease Dementia Taylor & Francis Pub.

CU-9 PDD Can be Diagnosed Simply and Unambiguously in Routine Clinical Practice  Diagnosis of PDD is straightforward in routine clinical practice using 3 simple principles – Established diagnosis of Parkinson’s disease – Developing dementia at least 1 to 2 yrs after onset of PD – Exclusion of other causes of dementia, eg, VaD, MSA, PSP

CU-10 Severe Neuroleptic Sensitivity Reactions in PDD and AD  Severe neuroleptic sensitivity reactions (NSR), characterized by severe parkinsonism, autonomic instability, increased confusion, rhabdomyolysis, and often death  Severe NSR occurs in – > 30% of DLB †‡§ and PDD † – 0% of AD †‡§ † Aarsland D, et al. J Clin Psych. 2005;66: ‡ McKeith I, et al. BMJ. 1992;305: § Ballard C, et al. Lancet. 1998;351:

CU-11 Cholinergic Deficits in PDD  There is established cholinergic deficit in PDD  The cholinergic deficits are associated with many of the key neuropsychiatric symptoms and cognitive deficits AuthorTechnique Disease subgroups ADPDPDD Perry, 1985Neurochem (ChAT)  Ruberg, 1986Neurochem (AChE)N/A // /  † Tiraboschi, 2000Neurochem (ChAT)  N/A  Mattila, 2001Neurochem (ChAT)N/A  ‡ Bohnen, 2003PET (AChE activity)  † AChE total/AChE 10S form. ‡ Included PD/PDD together.

CU-12 Conclusions  Lewy body-related alpha-synucleinopathy is the pathology predominantly associated with cognitive impairment in PDD  PDD can most effectively be diagnosed using simple clinical criteria based on the presence of PD and the time course of development of dementia  The shared cholinergic deficit in PDD and AD presents a common treatment target